| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
COMT is an enzyme involved in the inactivation of catecholamines, a neurotransmitter of the sympathetic nervous system. Its inhibitors are clinically practical use as a therapeutic agent for Parkinson's disease in Japan.
In our animal and cell experiment, glucose tolerance deteriorates under a high-fat diet by the COMT failure proved by insulin secretion decrease. Improvement of glucose intolerance with COMT metabolites proved that by improving insulin resistance.
The result of the influence on the metabolism of COMT inhibitors which are used in Parkinson's disease patients was investigated in glucose tolerance test, there were not observed problems with obvious metabolic abnormalities within therapeutic dose. However it appeared to require further consideration.
|
